Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.59 |
| ▸ | CDC25A | P30304 | 4/20 | 0.56 |
| ▸ | POLA1 | P09884 | 1/20 | 0.54 |
| ▸ | SRD5A1 | P18405 | 7/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 6/20 | 0.53 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.49 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | OSBP | P22059 | 1/20 | 0.48 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.48 |
| ▸ | EBP | Q15125 | 1/20 | 0.47 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 1/20 | 0.47 |
| ▸ | FNTB | P49356 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27321923 | 0.81 | OSBP (0.65) | POLA1SRD5A1NPC1L1USP2LMNA | |
| SCHEMBL3676831 | 0.79 | CYP2D6 (0.66) | CYP2D6CYP2C19INPP5DCDC25APOLA1 | |
| SCHEMBL2224276 | 0.79 | EPHA2 (0.55) | CYP2D6CYP2C19INPP5DCDC25APOLA1 | |
| SCHEMBL11459234 | 0.78 | CYP2D6 (0.67) | CYP2D6CYP2C19INPP5DCDC25APOLA1 | |
| SCHEMBL4021026 | 0.78 | CYP2D6 (0.67) | CYP2D6CYP2C19INPP5DCDC25APOLA1 | |
| SCHEMBL11468426 | 0.78 | CYP2D6 (0.67) | CYP2D6CYP2C19INPP5DCDC25APOLA1 | |
| SCHEMBL13769841 | 0.78 | CYP2D6 (0.67) | CYP2D6CYP2C19INPP5DCDC25APOLA1 | |
| SCHEMBL11459235 | 0.78 | CYP2D6 (0.67) | CYP2D6CYP2C19INPP5DCDC25APOLA1 | |
| SCHEMBL11470540 | 0.78 | CYP2D6 (0.67) | CYP2D6CYP2C19INPP5DCDC25APOLA1 | |
| SCHEMBL4021032 | 0.78 | CYP2D6 (0.67) | CYP2D6CYP2C19INPP5DCDC25APOLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011084721-A2 | CATIONIC MOLECULE AND METHOD OF USE | AGAVE PHARMA INC (US) | 2011-07-14 | — | — | WO | disclosed |
| EP-0799059-B1 | CATIONIC AMPHIPHILES AND PLASMIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORP (US) | 2002-07-31 | — | — | EP | disclosed |
| US-6383814-B1 | AEROSOLIZED SOLUTION INCLUDES BIOLOGICALLY ACTIVE MOLECULE, CATIONIC AMPHIPHILE FOR TRANSPORT OF ACTIVE MOLECULE INTO CELL, AND POLYETHYLENE GLYCOL-PHOSPHATIDYLETHANOLAMINE; GENE THERAPY; ANTISENSE AGENTS | GENZYME CORPORATION | 2002-05-07 | — | — | US | disclosed |
| US-20020013282-A1 | CATIONIC AMPHIPILE COMPOSITIONS FOR INTERACELLUAR DELIVERY OF THERAPEUTIC MOLECULES | MARSHALL JOHN (US) | 2002-01-31 | — | — | US | disclosed |
| US-6331524-B1 | ADMINISTERING COMPLEX OF SPERMIDINE CHOLESTEROL CARBAMATE AND POLYNUCLEOTIDE ENCODING RETINOBLASTOMA PROTEIN AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | GENZYME CORPORATION | 2001-12-18 | — | — | US | disclosed |
| EP-1007003-A1 | CATIONIC AMPHIPHILE COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | Genzyme Corporation (US) | 2000-06-14 | — | — | EP | disclosed |
| US-6071890-A | COMPLEX OF A BIOLOGICALLY ACTIVE MOLECULE SELECTED FROM A PROTEIN, SMALL MOLECULE, NUCLEIC ACIDS WITH A CATIONIC AMPHIPHILE | GENZYME CORPORATION (US) | 2000-06-06 | — | — | US | disclosed |
| EP-0954338-A2 | CATIONIC AMPHIPHILE/DNA COMPLEXES | Genzyme Corporation (US) | 1999-11-10 | — | — | EP | disclosed |
| EP-0954339-A2 | CATIONIC AMPHIPHILE COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | Genzyme Corporation (US) | 1999-11-10 | — | — | EP | disclosed |
| US-5948767-A | TRANSPORT OF ACTIVE MATERIAL INTO CELLS; DRUG DELIVERY | GENZYME CORPORATION (US) | 1999-09-07 | — | — | US | disclosed |
| US-5783565-A | FORM COMPLEXES WITH BIOLOGICALLY ACTIVE MOLECULES; GENE THERAPY | GENZYME CORPORATION (US) | 1998-07-21 | — | — | US | disclosed |
| US-5767099-A | CONTAINING LIPOPHILIC GROUPS DERIVED FROM STEROIDS | GENZYME CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| US-5747471-A | DNA, RNA AND ANTISENSE POLYNUCLEOTIDES FOR GENE THERAPY | GENZYME CORPORATION (US) | 1998-05-05 | — | — | US | disclosed |
| WO-1998013026-A1 | CATIONIC AMPHIPHILE COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1998-04-02 | — | — | WO | disclosed |
| US-5719131-A | GENE THERAPY | GENZYME CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| WO-1998002191-A2 | CATIONIC AMPHIPHILE COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1998-01-22 | — | — | WO | disclosed |
| WO-1998002190-A2 | CATIONIC AMPHIPHILE/DNA COMPLEXES | GENZYME CORPORATION (US) | 1998-01-22 | — | — | WO | disclosed |
| EP-0799059-A1 | CATIONIC AMPHIPHILES AND PLASMIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5650096-A | Cationic amphiphiles for intracellular delivery of therapeutic molecules | GENZYME CORPORATION (US) | 1997-07-22 | — | — | US | disclosed |
| WO-1996018372-A2 | CATIONIC AMPHIPHILES AND PLASMIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013282-A1 | CATIONIC AMPHIPILE COMPOSITIONS FOR INTERACELLUAR DELIVERY OF THERAPEUTIC MOLECULES | ANXA4, ABCB4, SLC43A1 | CYP2D6 3885/4885CYP2C19 4232/4885INPP5D 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.